Tafenoquine (Arakoda; Krintafel) for Malaria
Tafenoquine (Arakoda; Krintafel) for Malaria
July 1, 2019 (Issue: 1575)
The oral antimalarial tafenoquine succinate, a long-acting
analog of primaquine, has been approved by
the FDA in 2 different strengths. Arakoda (100-mg
tablets; Sixty Degrees) is indicated for the prophylaxis
of malaria in adults. Krintafel...more
- CDC. Yellow fever vaccine & malaria prophylaxis information, by country. Available at: https://wwwnc.cdc.gov. Accessed June 19, 2019.
- Advice for travelers. Med Lett Drugs Ther 2015; 57:52.
- DO Freedman. Tafenoquine: integrating a new drug for malaria prophylaxis into travel medicine practice. J Travel Med 2019; 26:(4).
- GD Shanks et al. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis 2001: 33:1968.
- BR Hale et al. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis 2003; 36:541.
- PE Nasveld et al. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother 2010; 54:792.
- MVG Lacerda et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med 2019; 380:215.
- A Llanos-Cuentas et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 2014; 383:1049.
- A Llanos-Cuentas et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med 2019; 380:229.
- P St. Jean et al. Impact of CYP2D6 on primaquine and tafenoquine efficacy in Plasmodium vivax malaria phase 3 clinical trials. Presented at ASTMH annual meeting 2018. Abstract 1734. Available at: https://www.astmh.org.
- H Motohashi and K Inui. Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J 2013; 15:581.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Tafenoquine (Arakoda; Krintafel) for Malaria
Article code: 1575c
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
